RSSDI releases guidelines for management of Hypertension in Diabetes Mellitus 2022

Catering to the pressing need to outline an evidence and experience-based comprehensive treatment yardstick, the first-ever Indian guideline for the management of hypertension in Diabetes Mellitus has been released by the RSSDI on the 15th of Dec 2022.

The guideline has been published in the latest issue of the International Journal of Diabetes in Developing Countries – the IJDDC.

The guideline recommends that :-

• Calcium channel blockers (CCBs) must be preferred over beta-blockers and thiazides in combination therapy with Angiotensin II Receptor blockers (ARBs) for better cardiovascular and renoprotection in diabetic hypertensive Indian patients.
• Cilnidipine to be a comparatively more effective and safer novel molecule as compared to conventional CCBs for Indian diabetic hypertensive patients (Grade A recommendation).
• ARBs must be preferred over ACEi in diabetic patients with hypertension, telmisartan or azilsartan being selected as the first-line agent (grade B recommendation).
• ARBs, either alone or in combination with CCBs, can be used for blood pressure (BP) control in diabetic patients.
• Among the CCBs, novel molecules (e.g.cilnidipine) are recommended in combination with ARBs for better cardiovascular and reno-protection in diabetic hypertensive patients.
• Cilnidipine is a comparatively more efective and safer novel molecule as compared to conventional CCBs for Indian diabetic hypertensive patients (grade A recommendation).